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Abstract: Atrial fibrillation is the commonest arrhythmia worldwide and is a growing problem.AF is responsible for 25% of all strokes, 
and these patients suffer greater mortality and disability. Warfarin has traditionally been the only successful therapy for stroke preven-
tion, but its limitations have resulted in underutilisation. Major progress has been made in AF research, leading to improved manage-
ment strategies. Better risk stratification permits identification of truly low-risk patients who do not require anticoagulation and we are 
able to simplify ourevaluation of a patient’s bleeding risk.
The advent of novel anticoagulants means warfarin is no longer the only choice for stroke prophylaxis. These drugs circumvent many 
of warfarin’s inconveniences, but onlylong-term study and use will conclusively demonstrate how they compare to warfarin. The land-
scape of stroke prevention in AF has changed with effective alternatives to warfarin available for the first time in 60 years—but each 
new option brings new considerations.
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Introduction
Atrial fibrillation (AF) is the most common   arrhythmia 
encountered worldwide, affecting 1% of the general 
population1 with a lifetime risk of 25% for adults.2 The 
prevalence of AF increases with age,3,4 with almost 
one in ten patients over 80 affected.1 AF is a grow-
ing problem and it is estimated that between 6 million 
and 16 million people in the US will suffer with the 
rhythm disorder by 2050.1,5 These projected increases 
are owed largely to the ageing population, and the 
increased survival of patients with chronic cardiac 
disorders which predispose to AF—such as ischae-
mic heart disease and heart failure.6,7 The presence 
of AF in these patients with underlying heart disease 
is associated with a worse outcome,8 and increased 
healthcare costs: AF is responsible for an estimated 
1% of the United Kingdom National Health Service 
expenditure in the UK.9
The most feared and devastating complication of 
AF is stroke. The presence of AF is an independent 
risk factor for stroke, conferring a five-fold increase 
in the stroke risk.10 AF is held responsible for up to a 
quarter of all strokes,11 and these patients have more 
severe strokes: greater mortality, longer hospital stay, 
increased disability.12–14 AF is also a significant risk 
factor  for  stroke  recurrence.15  There  is  substantial 
evidence to suggest that most thromboembolic com-
plications could be prevented with adequate pharma-
cological anticoagulation.16,17
Traditionally, vitamin K antagonists (eg, warfarin) 
were the only available therapeutic option for oral 
anticoagulation. Warfarin  provides  highly  effective 
prophylaxis against thromembolism.18 Unfortunately, 
warfarin has many limitations and inconveniences19 
which have contributed to reluctance amongst both 
patients  and  physicians  to  use  this  therapy.20  This 
variability in the management of stroke prevention 
in AF has seen renewed efforts in the past decade to 
establish validated risk stratification models and novel 
alternative  antithrombotic  therapies.  The  progress 
made in this sphere has offered increased guidance 
and choice to both clinicians and patients to improve 
the   prevention of stroke in atrial fibrillation.
This article reviews the current treatment options 
available for stroke prevention in AF, their evidence 
base, safety and efficacy. Attention is given to the novel 
oral anticoagulants which are available now or soon to 
become available, and their potential place in therapy.
Risk Stratification
The risk of stroke in AF is dependent upon the presence 
or absence of several risk factors.21,22   Traditionally 
these risk factors were used to stratify patients into 
“low”, “intermediate”, or “high” risk for stroke. Older 
guidelines  used  this  grouping  to  recommend  oral 
  anticoagulation  to  high-risk  patients,  aspirin  for 
  low-risk patients, and a choice of either anticoagula-
tion or aspirin for the intermediate   grouping. This had 
the potential of introducing confusion (for example, 
for intermediate-risk patients no definitive guidance 
was given as to whether to offer anticoagulation or 
aspirin) and also undertreating a cohort of patients at 
substantial risk of stroke.
There is evidence that aspirin does not reduce the 
risk of stroke in low-risk patients,23 and that warfarin 
is superior to aspirin for patients at intermediate risk 
of stroke.24,25 The CHADS2 score26 also classified a 
large number of patients into the intermediate group. 
These limitations spurred on the development of a 
risk stratification system that more reliably identifies 
truly low-risk patients, and minimises patients being 
denied oral anticoagulation when they would derive 
significant benefit from it.
The CHA2DS2VASc score [Table 1] was suggested 
as such a scheme to improve risk stratification for 
stroke, to focus more on the identification of such ‘truly 
low risk’ patients.27 The CHA2DS2VASc scoreis better 
at identifying truly low-risk patients, and   categorises 
fewer patients as intermediate risk.28 It has now been 
validated in various large real-world cohort of patients29 
and may even performbetter than CHADS2 in identify-
ing patients at high-risk of stroke. The CHA2DS2VASc 
score is now included in European guidelines on the 
management of atrial fibrillation.30
Bleeding is the most important and feared compli-
cation of anticoagulant therapy among clinicians and 
patients. Bleeding risk is a limiting factor in the pre-
scription of antithrombotic therapy, and leaves a sub-
stantial number of patients untreated when they have 
clear  indications  for  anticoagulation.31  Clinicians 
should undertake an assessment of a patient’s risk for 
bleeding before initiating anticoagulant therapy.32
The  novel  HAS-BLED  score33  was  developed 
to allow clinicians to assess simply and practically 
assess the individual risk of bleeding in their patients 
before initiating antithrombotic therapy, and makes 
clinicians think about the common correctable risk Stroke prevention in AF
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factors for bleeding, for example, uncontrolled blood 
pressure, concomitant aspirin/NSAID use with oral 
anticoagulation, labile INRs, etc [Table 2]. It allows 
periodic  reassessment  of  a  patient’s  bleeding  risk 
considers the quality of the anticoagulation control.34 
This risk score has been validated in a large cohort of 
real-world patients,35 and performs favourably when 
compared  to  other  scoring  schemes.36  The  HAS-
BLED  score  has  also  been  included  in  European 
guidelines,30 and when used in conjunction with the 
CHA2DS2VASc score it allows clinicians to make a 
simple and informed judgment as to the relative ben-
efits and risks of anticoagulation.
The Ideal Anticoagulant
The efficacy of warfarin as prophylaxis against stroke 
is established and unequivocal.18,37 Unfortunately, there 
are many limitations associated with warfarin [Table 3]: 
its narrow therapeutic window, slow onset and offset 
of action, unpredictable pharmacokinetics and phar-
macodynamics leading to variability in dose response 
amongst individuals and multiple drug and food inter-
actions. Due to these factors, warfarin requires close 
laboratory monitoring of coagulation via the INR and 
subsequent  dose  adjustments.  These  regular  clinic 
attendances bring an increased financial burden and 
inconvenience to patients. Thus many patients who are 
eligible for warfarin choose not to use it.38
A  clinically  viable  alternative  to  warfarin  will 
need to possess several key characteristics.39,40 Novel 
agents [Table 4] need to be proven to be predict-
ably at least as effective as warfarin in clinical tri-
als. Other key features include: oral administration, 
fixed dose   regimens, wide therapeutic windows, low 
propensity for food and drug interactions, predict-
able   pharmacokinetics and pharmacodynamics with 
little inter and intra patient variability [Table 5]. New 
therapies would of course need to be safe and well-
tolerated, with low frequency and severity of adverse 
effects. They should also obviate the need for regular 
coagulation monitoring.
Mechanism of Action and 
Pharmacokinetic Profile
warfarin
Warfarin  is  a  vitamin-K  antagonist  that  produces 
its  anticoagulant  effect  by  interfering  with  the 
cyclic interconversion of vitamin K and its epoxide. 
Vitamin K is a cofactor for the posttranslational carbox-
ylation of glutamate residues of vitamin K-dependent 
clotting factors(II, VII, IX, X).41,42 These coagulation 
factors  require  carboxylation  to  be  biologically 
active,   therefore when warfarin inhibits the vita-
min K conversion cycle it leads to hepatic synthesis 
of  decarboxylated  (or  partially  carboxylated)  pro-
teins with reduced coagulant activity.43 The effect of 
warfarin can be counteracted by vitamin K1 (either 
ingested in food or administered therapeutically) and 
this effect may persist for up to a week as vitamin K 
accumulates in the liver.
Warfarin has a high bioavailability,44 is absorbed 
quickly  and  reaches  maximal  plasma  concentra-
tions  within  90  minutes.45 Warfarin  has  a  half-life 
of 36-hours and predominantly circulates bound to 
albumin. Warfarin accumulates in the liver where it is 
metabolised by two pathways. The dose-response of 
warfarin is impacted on by environmental and genetic 
factors. Polymorphisms of genes that encode for the 
vitamin-K epoxide reductase enzyme and CYP2C9 
enzyme have been identified as the most important 
contributors  to  the  wide  inter-individual  variations 
in dose requirements.46–48 Drugs may influence the 
pharmacokinetics of warfarin by reducing GI absorp-
tion or interfering with metabolic clearance;49 drugs 
may also disrupt the pharmacodynamics of   warfarin 
by  inhibiting  synthesis  or  increasing  clearance  of 
  vitamin K-dependent clotting factors. Dietary intake 
of   vitamin K can also impact on the anticoagulant 
effect of warfarin.50
Direct Thrombin Inhibitors
The  final  step  of  the  coagulation  pathway  requires 
thrombin  to  convert  fibrinogen  to  fibrin.  Direct 
thrombin  inhibitors  bind  to  thrombin  and  prevent 
its  interaction  with  substrates;  this  inhibits  fibrin 
  production.51 The effect of this class of drugs also pre-
vents thrombin-mediated activation of activation of 
Factors V, VIII, XI, and XIII, and thrombin-  induced 
platelet-aggregation.52 Direct thrombin inhibitors can 
inhibit clot-bound and free thrombin, owing to the 
fact they bind directly to the active catalytic site.53 
Numerous parenteral direct thrombin inhibitors are 
available  (such  as    bivalirudin,  hirudin  and  lepiru-
din) but the lack of an oral preparation does not lend 
them to use in lifelong stroke prevention for patients 
with AF.Ahmad and Lip
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Ximelegatran  was  the  first  available  oral  direct 
thrombin inhibitor.54 It is a prodrug that is rapidly con-
verted to melegatran (its active form).55   Ximelegatran 
had twice daily fixed dosing with a fast onset and 
  offset of action. There were no food interactions,56 lit-
tle potential for drug interactions,57 and low variability 
in the dose-response relationship.58   Ximelegatran was 
withdrawn from the market in 2004 due to its poten-
tial to cause raised liver enzymes and some reported 
cases of fulminant hepatic failure.59
Dabigatran  etexilate  is  an  oral  prodrug  which 
is  converted  in  the  liver  to  its  active  compound, 
  dabigatran.60 Dabigatran is a competitive, direct and 
reversible inhibitor of thrombin.52 As detailed above, 
dabigatran exerts an effect on both clot-bound and 
free thrombin. Dabigatran has a fast onset of action 
(peak 0.5–4 hours), a half-life of 17 hours with multi-
ple doses (7–9 hours with single doses),62 and reaches 
clinical steady state within 2.5 days of   initiation.61 
Dabigatran is predominantly (80%) cleared by the 
kidneys.61  Neither  the  prodrug  nor  its  metabolite 
exert an effect on the CYP system, thus dabigatran 
lends itself to fewer food and drug interactions than 
  warfarin. Absorption of dabigatran may be delayed by 
food,63 and there is an age effect on pharmacokinetic 
parameters64 although no reported gender effect.65
Factor Xa Inhibitors
Factor Xa plays a key role in the common pathway 
of the clotting cascade. This protein is located at the 
junction of the intrinsic and extrinsic pathway, lead-
ing to the conversion of prothrombin to factor IIa 
(thrombin).  Thrombin  then  converts  fibrinogen  to 
fibrin, leading to clot formation. Parenterally admin-
istered heparin-based anticoagulants act by binding to 
antithrombin and producing a conformational change 
to inhibit both thrombin and factor X.66 Fondaparinux 
inhibits  factor  Xa  indirectly,  utilising  antithrombin 
as a cofactor and producing a conformational change 
similar to heparin to inhibit factor Xa—but it can only 
inhibit factor Xa in its free form.67 Trials have demon-
strated the efficacy of heparin-based anticoagulants 
improves with greater selectivity for FXa.68,69
The  emerging  direct  factor  Xa  inhibitors  do 
not  require  antithrombin  as  a  cofactor,  and  bind 
directly to the active site of factor Xa.70 Factor Xa 
has  fewer  effects  outside  of  the  clotting  cascade, 
so may cause fewer side-effects than direct thrombin 
inhibitors71 (although direct thrombin inhibitors may 
also have beneficial effects outside the coagulation 
pathway35).
Apixaban is an oral, selective, reversible72 direct 
factor Xa inhibitor.73 It has high oral   bioavailability74 
and onset of action is within three hours.60 The drug 
has a half-life of 12 hours75 and is cleared via mul-
tiple  pathways:  25%  renal,  75%  in  faeces.74  Data 
indicate that apixaban does not inhibit or induce CYP 
enzymes.77 Its absorption is not impacted by food.77
Rivaroxaban is an oral, reversible, direct factor 
Xa  inhibitor.78  It  inhibits  prothrombinase  activity, 
as well as free and clot-associated FXa activity in 
  plasma.79 It has high oral bioavailability80 and is rap-
idly absorbed with a half-life of 9 hours in healthy 
subjects81 and 12 hours in those aged over 75.82 It has 
a rapid onset of action with maximal concentrations 
Table 1. The CHA2DS2-vASc score for risk of stroke in 
  nonvalvular AF.
Risk factor score
Congestive cardiac failure 1
Hypertension 1
Age $75 2
Diabetes mellitus 1
Stroke/TIA/thromboembolism 1
vascular disease 1
Age 65–74 1
Female sex 1
Maximum score 9
notes: A  score  of  0  indicates  low  risk;  1  indicates  moderate  risk;   
$2  indicates  high  risk.  Congestive  cardiac  failure  is  defined  as  left 
ventricular  ejection  fraction  #40%.  Hypertension  is  defined  as  blood 
pressure consistently above 140/90 mmHg or treated hypertension on 
medication. Vascular disease is defined as previous myocardial infarction, 
peripheral arterial disease or aortic plaque.
Table 2. The HAS-BLeD score for bleeding risk.
Risk factor score
Hypertension 1
Abnormal renal/liver function 1 or 2
Stroke 1
Bleeding tendency 1
Labile INR 1
Age (eg. .65) 1
Drugs (eg. concomitant aspirin, NSAIDs, etc)  
or alcohol
1 or 2
Maximum score 9
notes:  A  score  of  0–2  indicates  low  risk  of  bleeding;  a  score  of 
$3 indicates high risk of bleeding. Hypertension is defined as a systolic 
blood pressure .160 mmHg. 1 point is awarded for each of abnormal 
renal or liver function, and drugs or alcohol.Stroke prevention in AF
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reached  between  2  and  4  hours.80  Rivaroxaban 
has a dual mode of elimination with no identified 
active circulating metabolite: one-third of the dose 
is renally cleared, the remainder being metabolized 
by the liver.83 The pharmacokinetics of rivaroxaban 
are dose-proportional84 and generally unaffected by 
gender, body weight or extremes of age.85 Although 
rivaroxaban  can  theoretically  be  affectedby  drugs 
that  interact  with  CYP3A4,76  a  low  potential  for 
  clinically significant drug or food interactions has 
been reported.86–88
Clinical Studies: Efficacy and Safety
warfarin
It was conclusively proved in a series of randomised 
control trials in the late eighties and early nineties 
that  warfarin  was  effective  prophylaxis  for  stroke 
prevention  in  atrial  fibrillation  when  compared  to 
placebo.88–93 In 1994 pooled data from five   studies 
demonstrated  that  warfarin  conferred  a  68%  risk 
reduction in stroke compared with no therapy, and 
with no increased risk of bleeding.94 A meta-analysis 
in 2002 showed that warfarin significantly reduced 
ischaemic  stroke  when  compared  to  aspirin,95  and 
this was confirmed in 2007 when a further analysis of 
almost 30,000 patients revealed that warfarin reduced 
strokes by 40%   compared to aspirin.96 The benefit of 
warfarin over aspirin was preserved when trials were 
confined to an elderly population.97
The ACTIVE-W trial98 in 2006 sought to identify 
whether a combination of aspirin and clopidogrel 
would be non-inferior when compared to warfarin. 
The study showed clearly that warfarin was supe-
rior  to  aspirin  and  clopidogrel,  and  was  stopped 
early due to the clear benefit of oral anticoagulation. 
The rates of major bleeding in the two study groups 
were comparable (2.4% per annum for clopidogrel 
and aspirin vs. 2.2% per annum for warfarin). In the 
ACTIVE-A  trial99  patients  deemed  unsuitable  for 
warfarin were given either aspirin alone or a com-
bination  of  aspirin  and  clopidogrel.  Aspirin  plus 
clopidogrel reduced the rate of ischaemic stroke by 
28% compared with aspirin alone. However, it is 
worth noting that the rates of major bleeding with 
aspirin and clopidogrel were 2.0% in the ACTIVE-
A study group. This figure is similar to the major 
bleeding rate of dual antiplatelet therapy observed in 
ACTIVE-W, and also to the rate of major bleeding 
with warfarin. Therefore, aspirin and clopidogrel in 
combination would not be a suitable alternative to 
warfarin in patients deemed high-risk for haemor-
rhage. Dual antiplatelet therapy may, however, be 
a therapeutic option for patients truly ineligible for 
warfarin for other reasons100 (inability or unwilling-
ness to undergo regular monitoring, for example).
Table 3. Limitations of warfarin.
•   Frequent monitoring necessitating regular clinic 
attendance
• Narrow therapeutic window
•   Slow onset and offset of action, requiring 3–6 days to 
reach therapeutic levels
• Long half-life
• Numerous drug and dietary interactions
•   Genetic polymorphishms exist which confer increased 
sesnsitivity or resistance to warfarin
•   Unpredictable pharmacodynamics and 
pharmacokinetics leading to inter and intra-individual 
variability in dose and metabolism
Table 4. Pharmacokinetic and pharmacodynamics properties of the novel anticoagulants.
Dabigatran Rivaroxaban Apixaban
Mechanism of action Direct thrombin inhibitor Direct factor Xa inhibitor Direct factor Xa inhibitor
Prodrug Double prodrug No No
Dosing frequency Twice daily Once daily Twice daily
Bioavailability % 6.5 50 80
Tmax 2 hours 2–4 hours 3 hours
Half-life 17 hours with multiple doses,  
7–9 hours with single doses
9 hours in healthy subjects, 
12 hours in elderly subjects
12 hours
Mode of excretion 80% cleared renally One-third cleared renally, two-
thirds metabolised by the liver
70% cleared in faeces, 
25% cleared renally
Age effect Affects pharmacokinetic parameters No No
Drug interactions Interaction with aspirin at high doses None reported None reportedAhmad and Lip
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Dabigatran
Dabigatran  was  initially  evaluated  in  2007  in  the 
phase  II  trial  PETRO:101  in  this  trial,  502  patients 
with nonvalvular AF were randomized to dabigatran 
50, 150, or 300 mg twice/day alone or combined with 
aspirin 81 or 325 mg/day versus open-label   warfarin 
in  patients  with  a  CHADS2  score  of  1  or  higher. 
Major bleeding was more common in patients tak-
ing  dabigatran  300  mg  with  aspirin  (6.25%)  com-
pared with dabigatran 300 mg alone (0%, P , 0.02). 
Thromboembolism  was  only  observed  in  patients 
randomised to dabigatran 50 mg.
The  RE-LY  trial  was  a  large  randomised  con-
trolled trial comparing dabigatran with warfarin.102 It 
was a phase III, blinded, noninferiority trial in 18,113 
patients with nonvalvular AF with a CHADS2 score of 
1 or higher or who were older than 65 years with cor-
onary artery disease.103 Patients were randomised to 
either dabigatran, at a dosage of 110 or 150 mg twice 
daily or warfarin titrated to a goal INR of 2–3. The pri-
mary efficacy outcomes of the study included stroke 
or systemic embolism. Efficacy outcomes occurred 
at 1.69% per year in patients assigned to   warfarin 
  compared  with  1.53%  in  the  dabigatran  110-mg 
group (RR 0.91, CI 0.74–1.11, P , 0.001 for nonin-
feriority, P = 0.34 for superiority compared with war-
farin) and 1.11% in the dabigatran 150-mg group (RR 
0.66, 95% CI 0.53–0.82, P , 0.001 for noninferiority 
and superiority compared with warfarin). This differ-
ence in effect between dabigatran 150 mg and warfa-
rin was found to occur at 2 months into the trial and 
was carried throughout until trial completion. Thus 
low-dose dabigatran was shown to be non-inferior to 
warfarin and high-dose dabigatran was shown to be 
superior to warfarin. No statistically significant dif-
ference was demonstrated between the groups for the 
secondary outcome of all-cause mortality (4.13% for 
warfarin vs. 3.75% for dabigatran 110 mg; RR 0.91, 
95% CI 0.80–1.03). There was, however, a numeric 
decrease in both dabigatran groups that approached 
significance for those receiving dabigatran 150 mg.
Major bleeding was the primary safety outcome, 
defined as a reduction in haemoglobin level of 2 g/dL, 
transfusion requiring at least 2 units of blood, or symp-
tomatic bleeding in a critical area or organ. Major 
haemorrhage occurred in 3.36% per year in patients 
taking warfarin, 2.71% in low-dose dabigatran (RR 
0.8, 95% CI 0.69–0.93, P = 0.003 vs. warfarin), and 
3.11%/year  in  high-dose  dabigatran  150-mg  group 
(RR 0.93, 95% CI 0.81–1.07, P = 0.031 vs warfarin). 
Thus major bleeding was less with 110 mg of dabiga-
tran when compared to warfarin, and rates of major 
haemorrhage are similar with 150 mg dabigatran and 
warfarin. High-dose dabigatran was associated with 
a significantly increased risk of major gastrointesti-
nal haemorrhage (1.51%) compared with dabigatran 
110 mg (1.12%) or warfarin (1.02%). However, all 
composite major bleeding rates were found to be sim-
ilar between dabigatran 150 mg and warfarin.
Discontinuation  rates  were  15%  for  dabigatran 
110 mg, 16% for dabigatran 150 mg, and 10% for 
warfarin after the first year of the trial; and 21% for 
dabigatran 110 mg, 21% for dabigatran 150 mg, and 
17% for warfarin at the end of the second year of the 
trial (P , 0.001 for dabigatran vs warfarin). The pri-
mary driver for this increased discontinuation of dab-
igatran was its propensity to cause dyspepsia: 11.8% 
for 110 mg and 11.3% for 150 mg compared to 5.8% 
for warfarin (P , 0.001). Thus, warfarin was better 
tolerated than dabigatran.
Dabigatran 150-mg was found to have an increased 
rate  of  myocardial  infarction  (0.74%)  when  com-
pared with warfarin (0.53%/year). This effect that 
trended towards, but did not reach, statistical sig-
nificance (RR 1.38, 95% CI 1–1.91, P = 0.04). It is 
possible that the increased occurrence of myocardial 
infarction  observed  in  patients  taking  dabigatran 
in this trial owes more to the protective effects of 
warfarin rather than an inherent risk associated with 
dabigatran  treatment.  A  meta-analysis  comparing 
warfarin and other treatment regimes showed that 
warfarin  was  associated  with  significant  reduction 
in myocardial infarction (relative risk,0.77; 95% CI, 
0.63–0.95; P , 0.01).
104
Table 5. Characteristics of the ideal anticoagulant.
• Equivalent efficacy to warfarin at least
• Predictable response
• wide therapeutic window
• Low inter and intra-patient variability
• Fixed oral dosing
• Low potential for drug and dietary interactions
• No need for regular coagulation monitoring
• Fast onset and offset of action
• Low incidence and severity of adverse effectsStroke prevention in AF
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A subgroup analysis of the RE-LY trial investi-
gated the safety and efficacy of dabigatran   compared 
to    warfarin  with  differing  achievements  in  INR 
  control.105 The  study  found  that  the  time  in  thera-
peutic  range  did  not  impact  on  the  original  trial’s 
findings with regard to efficacy or intracranial haem-
orrhage. A further subgroup analysis was undertaken 
in patients with a history of previous stroke or TIA.106 
The  effects  of  dabigatran  compared  with  warfarin 
were not significantly different in patients with a pre-
vious stroke or TIA in any other outcomes compared 
with other patients—confirming dabigatran’s role in 
secondary  prevention  and  supporting  the  findings 
of the original RE-LY trial. An analysis of patients 
undergoing cardioversion107 showed the risk of stroke 
and major haemorrhage on dabigatran was similar to 
warfarin.
A  network  meta-analysis  compared  dabigatran 
favourably  to  antiplatelet  therapy:108  dabigatran 
150  mg  reduced  stroke  risk  by  63%  compared  to 
aspirin alone and 61% compared to dual antiplatelet 
therapy, as well as 77% when compared to placebo.
Rivaroxaban
The oral direct factor Xa inhibitor rivaroxaban was 
compared to warfarin in the ROCKET-AF study.109 
This trial was a phase III, randomised, double-blind, 
event-driven  noninferiority  trial  with  over  14,000 
patients comparing rivaroxaban with warfarin in non-
valvular AF (at least two documented episodes) and 
a history of stroke, TIA, or non-CNS embolism or at 
least two independent risk factors for future stroke. 
Enrolment of patients without stroke, TIA, or sys-
temic embolism and only two risk factors was capped 
at 10% of the overall study population; all subse-
quently  enrolled  patients  were  required  to  have  at 
least three stroke risk factors or a history of stroke, 
TIA, or systemic embolism. 86% of the total popula-
tion had a CHADS2 score of 3 or higher.
Patients were randomised to rivaroxaban 20 mg 
once daily (or 15 mg once daily in patients with mod-
erate  renal  impairment),  or  dose-adjusted  warfarin 
titrated to a target INR of 2.5. The per-protocol, as-
treated primary analysis was designed to determine 
whether rivaroxaban was noninferior to warfarin for 
the primary end point of stroke or systemic embolism; 
if the noninferiority criteria were satisfied, then supe-
riority was analysed in the intent-to-treat population.
Rivaroxaban was similar to warfarin for the pri-
mary efficacy endpoint of prevention of stroke and 
systemic embolism (event rate 1.71 versus 2.16 per 
100  patient  years  for  rivaroxaban  versus  warfarin; 
hazard ratio [HR] 0.79, 95% confidence interval [CI] 
0.66–0.96, P , 0.001 for noninferiority). The stricter 
intention-to-treat analysis  also  showed  rivaroxaban 
was similar to warfarin but did not reach statistical 
significance  for  superiority:  event  rate  2.12  versus 
2.42  per  100  patient  years  for  rivaroxaban  versus 
warfarin; HR 0.88, 95% CI 0.74–1.03, P = 0.117 for 
superiority. Superiority was only demonstrated in the 
per-protocol  analysis  of  patients  who  continued  to 
receive treatment for the 40-month trial period: event 
rate 1.70 versus 2.15 per 100 patient years for rivar-
oxaban versus warfarin; HR 0.79, 95% CI 0.65–0.95, 
P = 0.015 for superiority.
Major  and  nonmajor  clinically  relevant  bleed-
ing  was  similar  with  rivaroxaban  and  warfarin: 
event rate 14.91 versus 14.52 per 100 patient years 
for rivaroxaban versus warfarin; HR 1.03, 95% CI 
0.96–1.11, P = 0.442. The rivaroxaban group demon-
strated significantly less fatal bleeding (0.2 versus 0.5 
per 100 patient years, HR 0.50, 95% CI 0.31–0.79, 
P = 0.003), intracranial haemorrhage (0.5 versus 0.7 
per 100 patient years; P = 0.02). However, signifi-
cantly more patients receiving rivaroxaban had a hae-
moglobin decrease of 2 g/dL or more (event rate 2.77 
versus 2.26 per 100 patient years, HR 1.22, 95% CI 
1.03–1.44, P = 0.019) and required a blood transfu-
sion (1.65 versus 1.32 per 100 patient years, HR 1.25, 
95% CI 1.01–1.55, P = 0.044).
The  number  of  patients  experiencing  a  serious 
adverse event was similar in the two groups (rivar-
oxaban  37.3%  versus  warfarin  38.2%)  as  was  the 
documentation of an adverse event requiring discon-
tinuation of the study drug (rivaroxaban 15.7% ver-
sus warfarin 15.2%). Premature discontinuation rates 
were also comparable, at approximately 23%. A higher 
percentage of patients taking rivaroxaban experienced 
epistaxis (10.1% versus 8.6%), and the rates of ALT 
elevation were the same in both groups (2.9%).
Apixaban
The AVERROES study was designed to evaluate the 
use of apixaban for stroke prophylaxis by comparing 
it to aspirin in patients unsuitable for warfarin.111 The 
study enrolled 5600 patients with AF who were either Ahmad and Lip
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intolerant of or unsuitable for warfarin and compared 
apixaban 5 mg twice daily (2.5 mg twice daily for 
patients aged over 80 years, weighing under 60 kg, or 
with renal impairment) with aspirin 81–324 mg/day. 
The study was prematurely because of an acceptable 
safety profile and benefit in favour of apixaban. After 
a year, patients taking apixaban were found to have 
a 55% reduction in the primary endpoint of stroke 
or systemic embolism (1.6% versus 3.7% per year, 
HR 0.45, 95% CI 0.32–0.62, P , 0.001). The rate of 
major bleeding was similar in both groups: 1.4% per 
year for apixaban and 1.2% per year for aspirin (HR 
1.13, 95% CI 0.74–1.75, P = 0.57). Aspirin was the 
less well-tolerated therapy.112
The ARISTOTLE trial has compared apixaban to 
warfarin in patients with atrial fibrillation.113 It is a 
randomised phase III, double-blind, international trial 
comparing apixaban 5 mg twice/day versus warfarin 
titrated to an INR between 2 and 3 in over 18,000 
patients.114 The primary outcome was stroke (either 
ischaemic or haemorrhagic) or systemic embolism, 
and the trial was designed to test for noninferiority. 
Secondary objectives included an analysis for superi-
ority with respect to the primary outcome and to the 
rates of major bleeding and all-cause mortality. The 
follow-up period was 1.8 years.
The rate of the primary outcome in ARISTOTLE 
was  1.27%  per  year  in  the  apixaban  group  versus 
1.60% per year in the warfarin group (hazard ratio 
with apixaban, 0.79; 95% confidence interval [CI], 
0.66 to 0.95; P , 0.001 for noninferiority; P = 0.01 
for superiority). This was primarily driven by a reduc-
tion in haemorrhagic stroke, as the rates of ischaemic 
stroke  were  comparable  with  warfarin:  0.97%  per 
year in the apixaban group versus 1.05% per year in 
the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 
to 1.13; P = 0.42). Conversely, rate of haemorrhagic 
stroke  was  0.24%  per  year  in  the  apixaban  group 
versus 0.47% per year in the warfarin group (hazard 
ratio, 0.51; 95% CI, 0.35 to 0.75; P , 0.001). Apixa-
ban demonstrated a benefit with regards to all-cause 
mortality compared to warfarin: rates of death from 
any cause were 3.52% in the apixaban group versus 
3.94% in the warfarin group (hazard ratio, 0.89; 95% 
CI, 0.80 to 0.99; P = 0.047). Apixaban was found to 
be safer than warfarin in regard to major bleeding: 
2.13% per year in the apixaban group versus 3.09% 
per year in the warfarin group (hazard ratio, 0.69; 95% 
CI, 0.60 to 0.80; P , 0.001). Drug discontinuation 
occurred less frequently with apixaban compared to 
warfarin: 25.3% versus 27.5% (P = 0.001). The aver-
age time spent in therapeutic INR was 62.2% for the 
warfarin-treated patients. The reported adverse and 
serious adverse effects were similar in both groups 
of patients.
patient Values and preferences
An important consideration when deciding on a ther-
apeutic strategy for stroke prophylaxis in patients 
with AF is that of patient preference. Patients will, 
generally speaking, be taking the prescribed thera-
pies for the duration of their lives so it is crucial 
that  they  are  adequately  informed.  Evidence  sug-
gests that well-informed patients are more compliant 
with therapy115 and have better outcomes.116 The pre-
dominant concern of patients is that of stroke,117 and 
many are willing to accept slightly increased bleed-
ing risks to avoid a stroke. Physicians tend to be 
more concerned with hospital admissions, whereas 
patients are ultimately worried about death.118 The 
AF-AWARE study also found that physicians tended 
to overestimate the burden of anticoagulant treat-
ment.118 By and large, patients are willing to accept 
the inconveniences of anticoagulation to avoid seri-
ous adverse outcomes.119 However, the use of deci-
sion-making aids leads to fewer patients opting for 
anticoagulation.120
The  advent  of  novel  anticoagulant  therapies  is 
changing the landscape of stroke prevention in atrial 
fibrillation, and will significantly impact on patient 
preference. The new agents circumvent many of the 
inconveniences  of  warfarin:  regular  INR  checks, 
dietary  restrictions,  drug  interactions.  They  also, 
however, bring with them their own considerations 
and caveats [Table 6].
There are no known antidotes currently available 
for  dabigatran,  rivaroxaban  or  apixaban  (although 
preliminary work is being done on a potential factor 
Xa inhibitor antidote,121 and a phase IV study is inves-
tigating various reversal strategies for dabigatran).122 
The benefit of not requiring regular INR monitoring 
is offset by the fact that there is no validated way to 
assess the anticoagulant effect or level of the drug. 
We are also yet to establish how successful anticoag-
ulant bridging prior to surgery can be achieved with 
the new agents [Table 7].Stroke prevention in AF
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Dabigatran and apixaban require twice daily dosing, 
which is not an issue for rivaroxaban. Patients with GI 
dysfunction must be counselled regarding dabigatran’s 
propensity to cause dyspepsia and increased rates of 
gastrointestinal bleeding. Dabigatran and rivaroxaban 
must be used with caution in patients with renal insuf-
ficiency, and the dose of dabigatran recommended by 
the FDA for renal impairment123 was not studied in 
the RE-LY trial.124 Concerns were raised following 
RE-LY of the increased (but small excess) number of 
myocardial infarction events in the dabigatran-treated 
group, but this finding has not been seen in the trials 
for  apixaban  or  rivaroxaban.  Furthermore,  supple-
mentary findings from the RE-LY trial125 reporting 
newly identified events in the dabigatran group found 
the difference in the myocardial infarction rates was 
less pronounced.
The  efficacy  and  safety  of  warfarin  has  been 
  established  over  the  last  two  decades,  and  it  is 
  readily reversed by vitamin K. Patients must be fully 
aware that, by definition, little is known regarding 
the   long-term safety and efficacy profiles of novel 
agents. Further research ought to enhance our knowl-
edge of and confidence in the new agents available for 
stroke prophylaxis in AF (such as the RELY-ABLE 
trial,126  an  extension  of  the  RE-LY  trial  focussing 
on patient safety), and future work must emphasise 
patient preference.
Place in Therapy
Warfarin has a clearly defined place in therapy, as the 
established gold standard antithrombotic for stroke 
prevention in atrial fibrillation. The optimal INR for 
AF patients is 2.0–3.0,127 with increased risk of throm-
boembolism and haemorrhage outside this range at 
either end. The benefit of warfarin is strongly linked 
to the proportion of time spent in the therapeutic INR 
range (time in therapeutic range, TTR).128 A string of 
outcome measures in AF are all linked to the quality 
of the INR control: stroke and systemic embolism, 
myocardial infarction, major bleeding and death.129 
Even modest TTR improvements of 5%–10% have 
profound beneficial effects on clinical outcomes.130 
TTR in clinical trials is typically 60%–65%, but this 
exceeds that routinely achieved in clinical practice.131 
Very low TTR may completely obliterate the poten-
tial benefit of warfarin. It has been demonstrated that 
self-monitoring improves the quality of INR control 
and therefore outcome measures.132 Despite its effi-
cacy, the limitations of warfarin mean that a large 
group of patients with AF are not receiving effective 
prophylaxis against stroke.
The ultimate place in therapy of the novel oral 
anticoagulants  is  yet  to  be  established.  Currently, 
only dabigatran has been improved by the FDA and 
incorporated  into  guidelines.  The  US  guidelines133 
recommend dabigatran 150 mg BD as an alternative 
to warfarin (or 75 mg for patients with renal impair-
ment). The European guidelines30 currently recom-
mend  150  mg  dabigatran  twice  a  day  for  patients 
at  low  bleeding  risk  (HAS-BLED  score  0–2)  and 
110 mg dabigatran twice a day for those at high risk 
of  bleeding  (HAS-BLED  score  3  or  greater).  The 
Table 6. Potential limitations of new anticoagulants.
• No known antidote
• Lack of validated tests to monitor anticoagulant effect
• It is difficult to assess compliance
•   A method of anticoagulant bridging prior to surgery has 
not been established
• Unknown long-term safety profile
• Unknown true cost-effectiveness compared to warfarin
• No head-to-head studies of new agents
•   Dabigatran and apixaban require twice daily dosing, 
which may promote forgetfulness
• Dabigatran has been associated with GI side-effects
Table 7. Anticoagulant bridging.
•   There are no randomised trials evaluating peri-
operative outcomes in surgical patients taking novel 
oral anticoagulants
•   In the presence of normal renal function, it is advised 
that dabigatran can be stopped 24-hours prior to 
surgery139
•   with renal impairment or high risk of bleeding, 
dabigatran should be discontinued 2–4 days prior to 
surgery
•   In high-risk patients, a laboratory measure of 
anticoagulation ought to be sought
•   Anticoagulant bridging raises the issue of patients 
entering a prothrombotic state following cessation of a 
novel agent: in ROCKET-AF, there was a significantly 
increased risk of stroke in the rivaroxaban arm in the 
28-day period after rivaroxaban was stopped and 
patients were transitioned to another anticoagulant
•   The decision regarding how to bridge anticoagulant 
therapy requires the judgment of an experienced 
clinician who must considerthe type of surgery, the 
relative risk of bleeding and thromboembolism, the 
renal function and the quality of anticoagulationAhmad and Lip
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Canadian guidelines134 also recommend dabigatran as 
an alternative to warfarin.
Rivaroxaban and apixaban have completed phase 
III trials and will now undergo analysis and approval 
before their inclusion in guidelines. These two factor 
Xa inhibitors have not been shown to cause signifi-
cant GI upset, so may represent an appealing treat-
ment option for those patients unsuited to warfarin 
and unable to tolerate dabigatran due to dyspepsia. It 
is difficult to offer speculative comparisons between 
the  new  agents  based  on  their  study  designs.  For 
example, it may be tempting to infer that rivaroxaban 
is has more proven efficacy in high-risk patients as 
ROCKET-AF included few low-risk patients whereas 
RE-LY had significantly more (32% of patients in 
RE-LY had a CHADS2 score of 0–1, compared to ,1% 
for ROCKET-AF). Given the results of the ATLAS-
ACS2 trial138 (where rivaroxaban reduced the risk of 
the composite end point of death from cardiovascular 
causes, myocardial infarction, or stroke in patients 
with  a  recent  acute  coronary  syndrome),  rivaroxa-
ban may find favour with clinicians treating patients 
  following  acute  coronary  syndromes.    Conclusive 
comparisons between the new and emerging agents 
cannot be made until they have been   evaluated against 
each other in trials.
As new agents are becoming available to clini-
cians for prevention of stroke in AF, new consider-
ations must be undertaken [Table 8]. Patients who are 
Table 8. Cost-effectiveness of new agents.
• Cost will be a major barrier to use for the new agents
• warfarin is an established and cheap generic drug
•   Only dabigatran has been compared to warfarin in cost-
effectiveness analyses, both with favourable results for 
the new drug
•   One analysis136 suggested high-dose dabigatran was 
cost-effective as long as the cost was less than $13.70 
(roughly double the current US pricing)
•   A further analysis137 suggested that dabigatran was 
cost-effective in high-risk stroke patients unless they 
had exceptionally good INR control
•   Cost-effective analyses based on trial data may not 
reflect real-world clinical practice
•   Collateral costs (including physician time for dose-
adjustments and patient transport to clinics) must be 
incorporated into future analyses
•   More experience with the new agents is mandatory 
before meaningful conclusions on their cost-
effectiveness can be made
well-  established on warfarin with good quality INR 
control are unlikely to derive sufficient benefit to war-
rant switching to a new drug. The safety data avail-
able for the novel anticoagulants is reassuring, but 
long-term data is mandatory as patients will mostly 
be maintained on thromboprophylaxis for the dura-
tion of their lives. Emphasis must be given to individ-
ual patient characteristics, and patient preferences.
conclusions
For six decades, warfarin has been the only available 
therapeutic strategy for prophylaxis against stroke in 
patients with AF. Its limitations have led to its under-
utilisation and wide variability in AF management. 
Major progress has been made in AF research, provid-
ing clinicians with improved management strategies. 
Better  risk  stratification  schemes  permits  accurate 
identification of truly low-risk patients who do not 
require anticoagulation, and those patients who ought 
to be receiving antithrombotic therapy. We are also 
able to simply and practically evaluate a patient’s risk 
in relation to bleeding, enabling risk-benefit decisions 
to be made in a more straightforward manner.
The advent of novel anticoagulants means that war-
farin is no longer the only choice for effective stroke 
prophylaxis. Clinicians will be tasked with coming to 
terms with the strengths and weaknesses of each new 
therapeutic option and employing them in appropriate 
settings. Only long-term study and use of novel anti-
coagulants will conclusively demonstrate how these 
drugs measure up to warfarin in terms of efficacy, 
safety and cost-effectiveness (see Table 8). The nature 
of AF thromboprophylaxis means that patients will 
likely be receiving a drug lifelong, so the importance 
of long-term data for new agents and an emphasis on 
patient values and preference cannot be overstated. 
The landscape of stroke prevention in atrial fibrilla-
tion has changed and will continue evolve as research 
continues into newer drugs135—and with each new 
management option comes new considerations.
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